![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Mousa Al Omari, Yousef Khader, Ali Shakir Dauod, Othman Ahmed Beni Yonis & Adi Harbi Mohammad Khassawneh. (2016) Vildagliptin efficacy in combination with metformin among Jordanian patients with type 2 diabetes mellitus inadequately controlled with metformin. Journal of Drug Assessment 5:1, pages 29-33.
Read now
Read now
Bruno Detournay, Serge Halimi, Julien Robert, Céline Deschaseaux & Sylvie Dejager. (2015) Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database. Vascular Health and Risk Management 11, pages 417-425.
Read now
Read now
Antoni Sicras-Mainar & Ruth Navarro-Artieda. (2014) Use of metformin and vildagliptin for treatment of type 2 diabetes in the elderly. Drug Design, Development and Therapy 8, pages 811-818.
Read now
Read now
Flavia Franconi & Ilaria Campesi. (2014) Sex and gender influences on pharmacological response: an overview. Expert Review of Clinical Pharmacology 7:4, pages 469-485.
Read now
Read now
Chetan S Karyekar, Shoba Ravichandran, Elsie Allen, Douglas Fleming & Robert Frederich. (2013) Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus. Clinical Interventions in Aging 8, pages 419-430.
Read now
Read now
Sylvie Dejager, Anja Schweizer & James E Foley. (2012) Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus. Vascular Health and Risk Management 8, pages 339-348.
Read now
Read now
Articles from other publishers (18)
Thaer Idrees, Iris A Castro-Revoredo, Alexandra L Migdal, Emmelin Marie Moreno & Guillermo E Umpierrez. (2022) Update on the management of diabetes in long-term care facilities. BMJ Open Diabetes Research & Care 10:4, pages e002705.
Crossref
Crossref
Markéta Kubíčková. (2019) Specifics of diabetes in old age. Interní medicína pro praxi 21:4, pages 223-227.
Crossref
Crossref
Giorgio Sesti, Angelo Avogaro, Sara Belcastro, Benedetta Maria Bonora, Marina Croci, Giuseppe Daniele, Marco Dauriz, Francesco Dotta, Caterina Formichi, Simona Frontoni, Cecilia Invitti, Emanuela Orsi, Fabiana Picconi, Veronica Resi, Enzo Bonora & Francesco Purrello. (2019) Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus. Acta Diabetologica 56:6, pages 605-617.
Crossref
Crossref
G. Sesti, R. Antonelli Incalzi, E. Bonora, A. Consoli, A. Giaccari, S. Maggi, G. Paolisso, F. Purrello, G. Vendemiale & N. Ferrara. (2018) Management of diabetes in older adults. Nutrition, Metabolism and Cardiovascular Diseases 28:3, pages 206-218.
Crossref
Crossref
Katsunori Suzuki, Yurie Mistuma, Takaaki Sato & Mariko Hatta. (2015) Sitagliptin for Elderly Patients Aged 75 Years or Older with Inadequately Controlled Type 2 Diabetes with Common Antidiabetes Treatments. International Journal of Clinical Medicine 06:09, pages 672-681.
Crossref
Crossref
Dominique Simon, Bruno Detournay, Evelyne Eschwege, Stephane Bouée, Jacques Bringer, Claude Attali & Sylvie Dejager. (2014) Use of Vildagliptin in Management of Type 2 Diabetes: Effectiveness, Treatment Persistence and Safety from the 2-Year Real-Life VILDA Study. Diabetes Therapy 5:1, pages 207-224.
Crossref
Crossref
A. Penfornis, I. Bourdel-Marchasson, S. Quéré & S. Dejager. (2014) Étude HYPOCRAS : comparaison en vie réelle chez des patients âgés diabétiques de type 2 d’un traitement par inhibiteur de la DPP-4 versus autres antidiabétiques oraux en ajout à la metformine. Médecine des Maladies Métaboliques 8:1, pages 47-55.
Crossref
Crossref
Thundiparambil Azeez Sonia & Chandra P. Sharma. 2014. Oral Delivery of Insulin. Oral Delivery of Insulin
1
57
.
Anja Schweizer & Sylvie Dejager. (2013) Experience with Vildagliptin in Patients ≥75 Years with Type 2 Diabetes and Moderate or Severe Renal Impairment. Diabetes Therapy 4:2, pages 257-267.
Crossref
Crossref
Serge Halimi. (2013) Prise en charge du diabète de type 2 : anciens ou nouveaux médicaments, comment choisir ?. La Presse Médicale 42:5, pages 861-870.
Crossref
Crossref
Alexandra Kautzky-Willer & Rosa Lemmens-Gruber. 2012. Sex and Gender Differences in Pharmacology. Sex and Gender Differences in Pharmacology
307
340
.
A. Penfornis, I. Bourdel-Marchasson, S. Quere & S. Dejager. (2012) Real-life comparison of DPP4-inhibitors with conventional oral antidiabetics as add-on therapy to metformin in elderly patients with type 2 diabetes: The HYPOCRAS study. Diabetes & Metabolism 38:6, pages 550-557.
Crossref
Crossref
Matthias Blüher. (2012) Efficacy and safety of vildagliptin in clinical practice-results of the PROVIL-study. World Journal of Diabetes 3:9, pages 161.
Crossref
Crossref
Gayatri Sreemantula & Santosh Shankarnarayan. 2012. Managing Diabetes. Managing Diabetes
61
89
.
George P Samraj. (2011) Vildagliptin for the treatment of diabetes. Therapy 8:6, pages 703-719.
Crossref
Crossref
Sylvie Dejager & Anja Schweizer. (2011) Minimizing the risk of hypoglycemia with vildagliptin: Clinical experience, mechanistic basis, and importance in type 2 diabetes management. Diabetes Therapy 2:2, pages 51-66.
Crossref
Crossref
A. Schweizer, S. Dejager, J. E. Foley, Q. Shao & W. Kothny. (2011) Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials. Diabetes, Obesity and Metabolism 13:1, pages 55-64.
Crossref
Crossref
Gillian M. Keating. (2010) Vildagliptin. Drugs 70:16, pages 2089-2112.
Crossref
Crossref